202 related articles for article (PubMed ID: 35795973)
1. Role of single nucleotide polymorphisms of the HSD3B1 gene (rs6203 and rs33937873) in the prediction of prostate cancer risk.
Amrousy YM; Haffez H; Abdou DM; Atya HB
Mol Med Rep; 2022 Aug; 26(2):. PubMed ID: 35795973
[TBL] [Abstract][Full Text] [Related]
2. Estrogen synthesis genes CYP19A1, HSD3B1, and HSD3B2 in hypertensive disorders of pregnancy.
Shimodaira M; Nakayama T; Sato I; Sato N; Izawa N; Mizutani Y; Furuya K; Yamamoto T
Endocrine; 2012 Dec; 42(3):700-7. PubMed ID: 22638611
[TBL] [Abstract][Full Text] [Related]
3. HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study.
Hearn JWD; AbuAli G; Reichard CA; Reddy CA; Magi-Galluzzi C; Chang KH; Carlson R; Rangel L; Reagan K; Davis BJ; Karnes RJ; Kohli M; Tindall D; Klein EA; Sharifi N
Lancet Oncol; 2016 Oct; 17(10):1435-1444. PubMed ID: 27575027
[TBL] [Abstract][Full Text] [Related]
4. Association of HSD3B1 Genotype With Response to Androgen-Deprivation Therapy for Biochemical Recurrence After Radiotherapy for Localized Prostate Cancer.
Hearn JWD; Xie W; Nakabayashi M; Almassi N; Reichard CA; Pomerantz M; Kantoff PW; Sharifi N
JAMA Oncol; 2018 Apr; 4(4):558-562. PubMed ID: 29049492
[TBL] [Abstract][Full Text] [Related]
5. Association of Missense Polymorphism in HSD3B1 With Outcomes Among Men With Prostate Cancer Treated With Androgen-Deprivation Therapy or Abiraterone.
Shiota M; Narita S; Akamatsu S; Fujimoto N; Sumiyoshi T; Fujiwara M; Uchiumi T; Habuchi T; Ogawa O; Eto M
JAMA Netw Open; 2019 Feb; 2(2):e190115. PubMed ID: 30794306
[TBL] [Abstract][Full Text] [Related]
6. Independent Validation of Effect of HSD3B1 Genotype on Response to Androgen-Deprivation Therapy in Prostate Cancer.
Agarwal N; Hahn AW; Gill DM; Farnham JM; Poole AI; Cannon-Albright L
JAMA Oncol; 2017 Jun; 3(6):856-857. PubMed ID: 28208175
[TBL] [Abstract][Full Text] [Related]
7. HSD3B1 Genotype and Clinical Outcomes in Metastatic Castration-Sensitive Prostate Cancer.
Hearn JWD; Sweeney CJ; Almassi N; Reichard CA; Reddy CA; Li H; Hobbs B; Jarrard DF; Chen YH; Dreicer R; Garcia JA; Carducci MA; DiPaola RS; Sharifi N
JAMA Oncol; 2020 Apr; 6(4):e196496. PubMed ID: 32053149
[TBL] [Abstract][Full Text] [Related]
8. HSD3B1 variant and androgen-deprivation therapy outcome in prostate cancer.
Han FF; Ren LL; Xuan LL; Lv YL; Liu H; Gong LL; An ZL; Liu LH
Cancer Chemother Pharmacol; 2021 Jan; 87(1):103-112. PubMed ID: 33141329
[TBL] [Abstract][Full Text] [Related]
9. Left ventricular structure and function in relation to steroid biosynthesis genes in a white population.
Jin Y; Kuznetsova T; Citterio L; Thijs L; Messaggio E; Casamassima N; Manunta P; Fagard R; Bianchi G; Staessen JA
Am J Hypertens; 2012 Sep; 25(9):986-93. PubMed ID: 22673022
[TBL] [Abstract][Full Text] [Related]
10. The association between missense polymorphisms in SRD5A2 and HSD3B1 and treatment failure with abiraterone for castration-resistant prostate cancer.
Shiota M; Akamatsu S; Narita S; Sumiyoshi T; Fujiwara M; Uchiumi T; Ogawa O; Habuchi T; Eto M
Pharmacogenomics J; 2021 Aug; 21(4):440-445. PubMed ID: 33649516
[TBL] [Abstract][Full Text] [Related]
11. HSD3B1 and Response to a Nonsteroidal CYP17A1 Inhibitor in Castration-Resistant Prostate Cancer.
Almassi N; Reichard C; Li J; Russell C; Perry J; Ryan CJ; Friedlander T; Sharifi N
JAMA Oncol; 2018 Apr; 4(4):554-557. PubMed ID: 29049452
[TBL] [Abstract][Full Text] [Related]
12. Germline HSD3B1 Genetics and Prostate Cancer Outcomes.
Thomas L; Sharifi N
Urology; 2020 Nov; 145():13-21. PubMed ID: 32866512
[TBL] [Abstract][Full Text] [Related]
13. Association of HSD3B1 and HSD3B2 gene polymorphisms with essential hypertension, aldosterone level, and left ventricular structure.
Shimodaira M; Nakayama T; Sato N; Aoi N; Sato M; Izumi Y; Soma M; Matsumoto K
Eur J Endocrinol; 2010 Oct; 163(4):671-80. PubMed ID: 20660004
[TBL] [Abstract][Full Text] [Related]
14. HSD3B1 status as a biomarker of androgen deprivation resistance and implications for prostate cancer.
Hettel D; Sharifi N
Nat Rev Urol; 2018 Mar; 15(3):191-196. PubMed ID: 29231195
[TBL] [Abstract][Full Text] [Related]
15. Prevalence and Prognostic Value of the Polymorphic Variant 1245A>C of HSD3B1 in Castration-resistant Prostate Cancer.
Stangl-Kremser J; Lemberger U; Hassler MR; Bruchbacher A; Ilijazi D; Garstka N; Kramer G; Haitel A; Abufaraj M; Shariat SF
Clin Genitourin Cancer; 2019 Oct; 17(5):389-394. PubMed ID: 31331867
[TBL] [Abstract][Full Text] [Related]
16. Germline Variant in HSD3B1 (1245 A > C) and Response to Abiraterone Acetate Plus Prednisone in Men With New-Onset Metastatic Castration-Resistant Prostate Cancer.
Hahn AW; Gill DM; Nussenzveig RH; Poole A; Farnham J; Cannon-Albright L; Agarwal N
Clin Genitourin Cancer; 2018 Aug; 16(4):288-292. PubMed ID: 29674118
[TBL] [Abstract][Full Text] [Related]
17. Genetic variation in the HSD3B1 gene and recurrent spontaneous abortions.
Ntostis P; Peraki O; Boulgari A; Agiannitopoulos K; Pantos K; Lamnissou K
J Matern Fetal Neonatal Med; 2012 Apr; 25(4):408-10. PubMed ID: 21631238
[TBL] [Abstract][Full Text] [Related]
18. Expression and gene variation studies deny association of human HSD3B1 gene with aldosterone production or blood pressure.
Verwoert GC; Hofland J; Amin N; Mattace-Raso FU; Sijbrands EJ; Hofman A; van den Meiracker AH; Uitterlinden AG; van Duijn CM; de Jong FH; Danser AH
Am J Hypertens; 2015 Jan; 28(1):113-20. PubMed ID: 24951726
[TBL] [Abstract][Full Text] [Related]
19. Association between polymorphisms in HSD3B1 and UGT2B17 and prostate cancer risk.
Park JY; Tanner JP; Sellers TA; Huang Y; Stevens CK; Dossett N; Shankar RA; Zachariah B; Heysek R; Pow-Sang J
Urology; 2007 Aug; 70(2):374-9. PubMed ID: 17826523
[TBL] [Abstract][Full Text] [Related]
20. Treatment with abiraterone and enzalutamide does not overcome poor outcome from metastatic castration-resistant prostate cancer in men with the germline homozygous HSD3B1 c.1245C genotype.
Lu C; Terbuch A; Dolling D; Yu J; Wang H; Chen Y; Fountain J; Bertan C; Sharp A; Carreira S; Isaacs WB; Antonarakis ES; De Bono JS; Luo J
Ann Oncol; 2020 Sep; 31(9):1178-1185. PubMed ID: 32387417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]